DSP-0038 is under clinical development by Sunovion Pharmaceuticals and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DSP-0038’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DSP-0038 overview

DSP-0038 is under development for the treatment of Alzheimer's disease psychosis. It is administered through oral route. The drug candidate is a bi-specific compounds that target multiple 5-HT1A and 5-HT2A. It is developed based on centaur chemist artificial intelligence (AI) powered platform.

Sunovion Pharmaceuticals overview

Sunovion Pharmaceuticals (Sunovion), a subsidiary of Sumitomo Dainippon Pharmaceutical Co Ltd, is a research-based pharmaceutical company. It discovers, develops, and marketize therapeutic products that focus on the treatment of the central nervous system and respiratory disorders. Its major products include eslicarbazepine acetate tablets, lurasidone HCl tablets, eszopiclone tablets, glycopyrrolate inhalation solution and levalbuterol tartrate inhalation aerosol. The company’s product candidates are intended for the treatment of schizophrenia, neuropathic pain, bipolar depression, treatment-resistant depression, agitation in Alzheimer’s disease, and Parkinson’s disease, among others. It has partnerships with various pharmaceutical companies such as Psychogenics and others. Sunovion is headquartered in Marlborough, Massachusetts, the US.

For a complete picture of DSP-0038’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.